Noradrenergic Depression of Neuronal Excitability in the Entorhinal Cortex via Activation of TREK-2 K⁺ Channels*[S]

From the Department of Pharmacology, Physiology and Therapeutics, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, North Dakota 58203, the Neuro-behavioural Biology Center, Institute of Science and Technology for Research and Development, Mahidol University, Salaya Nakornpathom 73170, Thailand, the Center for Neuroscience and Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand, and the Department of Human Genetics, Emory University, Atlanta, Georgia 30322

Zhaoyang Xiao,[a] Pan-Yue Deng,[a] Lalida Rojanathammanee,[a] Chuanxiu Yang,[a] Laurel Grisanti,[a] Kannika Permpoonputtana,[a] David Weinshenker,[b] Van A. Doze,[b] James E. Porter,[b] and Saobo Lei[a][b][‡][¶]

Received for publication, September 2, 2008, and in revised form, February 5, 2009 Published, JBC Papers in Press, February 25, 2009, DOI 10.1074/jbc.M806760200

The entorhinal cortex is closely associated with the consolidation and recall of memories, Alzheimer disease, schizophrenia, and temporal lobe epilepsy. Norepinephrine is a neurotransmitter that plays a significant role in these physiological functions and neurological diseases. Whereas the entorhinal cortex receives profuse noradrenergic innervations from the locus coeruleus of the pons and expresses high densities of adrenergic receptors, the function of norepinephrine in the entorhinal cortex is still elusive. Accordingly, we examined the effects of norepinephrine on neuronal excitability in the entorhinal cortex and explored the underlying cellular and molecular mechanisms. Application of norepinephrine-generated hyperpolarization and decreased the excitability of the neurons in the superficial layers with no effects on neuronal excitability in the deep layers of the entorhinal cortex. Norepinephrine-induced hyperpolarization was mediated by α2A, adrenergic receptors and required the functions of Gαi, proteins, adenylyl cyclase, and protein kinase A. Norepinephrine-mediated depression on neuronal excitability was mediated by activation of TREK-2, a type of two-pore domain K⁺ channel, and mutation of the protein kinase A phosphorylation site on TREK-2 channels annulled the effects of norepinephrine. Our results indicate a novel action mode in which norepinephrine depresses neuronal excitability in the entorhinal cortex by disinhibiting protein kinase A-mediated tonic inhibition of TREK-2 channels.

The entorhinal cortex (EC)[2] is an essential structure in the limbic system that is closely related to emotional control (1), consolidation and recall of memories (2, 3), Alzheimer disease (4, 5), schizophrenia (6, 7), and temporal lobe epilepsy (8, 9). The physiological and pathological roles of the EC are likely to be determined by its unique position in the brain; the EC serves as the interface to control the flow of information into and out of the hippocampus. Afferents from the olfactory structures, parasubiculum, perirhinal cortex, claustrum, amygdala, and neurons in the deep layers of the EC (layers V–VI) (10, 11) converge onto the superficial layers (layer II/III) of the EC, whereas the axons of principal neurons in layer II form the major component of perforant path that innervates the dentate gyrus and CA3 (12), and those of the pyramidal neurons in layer III form the temporoammonic pathway and synapse onto the distal dendrites of pyramidal neurons in the CA1 and subiculum (12–14). The output from the hippocampus is then projected to the deep layers of the EC that relay information back to the superficial layers (15–18) and to other cortical areas (10).

The EC receives abundant noradrenergic projections from the locus coeruleus in the brain stem (19–21) and expresses α1 (22), α2 (23–25), and β (26) adrenergic receptors (ARs), although the identities of cells expressing these ARs in the EC remain to be determined. Accordingly, application of norepinephrine (NE) in the EC has been shown to inhibit glutamatergic transmission via activation of α2 ARs (27, 28) and facilitate GABAergic transmission via activation of α1, ARs (29). The concerted effects of NE on glutamatergic and GABAergic transmission would result in powerful inhibition in the EC likely contributing to its antiepileptic actions observed in this brain region (22, 30). Whereas application of NE has been shown to generate membrane hyperpolarization in a proportion (~54%) of principal neurons in layer II of the EC (28) via α2 AR-mediated activation of K⁺ channels (27), which may partially explain its inhibitory effects on glutamatergic transmission, the following questions still remain unaddressed. First, what subtype(s) of α2 ARs is/are involved in NE-mediated hyperpolarization in the EC, because members of the α2 AR family include the α2A, α2B, and α2C subtypes (31)? Second, does NE have any effects on the excitability of neurons in other layers of the EC, because the superficial layers are the sender and the deep layers are the recipient of hippocampal information? Third, which type(s) of α2 ARs is/are involved in NE-mediated hyperpolarization in the EC, because members of the α2 AR family include the α2A, α2B, and α2C subtypes (31)? Second, does NE have any effects on the excitability of neurons in other layers of the EC, because the superficial layers are the sender and the deep layers are the recipient of hippocampal information? Third, which type(s) of monophosphate; (R)₃-cAMPS, (R)₃-adenosine 3',5'-cyclic monophosphorothioate; GABAergic, γ-aminobutyric acid-mediated; GDP-β-S, guanosine 5'-O-(2-thiodiphosphate).
Adrenergic Activation of TREK-2 in the EC

K⁺ channels is/are involved in NE-mediated hyperpolarization? Finally, what are the signaling mechanisms underlying NE-induced hyperpolarization in the EC? In the present study, we address these questions, and our results demonstrate that NE generates membrane hyperpolarization in the superficial layers, especially layer III, with no effects on neuronal excitability in the deep layers (V/VI) of the EC. NE activates TREK-2, a two-pore domain K⁺ channel, via α2A AR-mediated inhibition of the protein kinase A (PKA) pathway. Our results provide a novel cellular and molecular mechanism that may at least partially explain the antiepileptic effects of NE in the EC as well as its roles in learning and memory.

EXPERIMENTAL PROCEDURES

Slice Preparation—Horizontal brain slices (400 μm), including the EC, subiculum, and hippocampus, were cut using a vibrating blade microtome (VT1000S, Leica, Wetzlar, Germany) from 13- to 20-day-old Sprague-Dawley rats as described previously (29, 32–35). After being deeply anesthetized with isoflurane, rats were decapitated and their brains were dissected out in ice-cold saline solution that contained (in mM) 130 NaCl, 24 NaHCO3, 3.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 5.0 MgCl2, and 10 glucose, saturated with 95% O2 and 5% CO2, pH 7.4. Slices were initially incubated in the above solution at 35 °C for 40 min for recovery and then kept at room temperature (−24 °C) until use. All animal procedures conformed to the guidelines approved by the University of North Dakota Animal Care and Use Committee.

Whole Cell Recordings from the EC Neurons—Whole cell patch clamp recordings using an Axopatch 200B or two Multi-clamp 700B amplifiers (Molecular Devices, Sunnyvale, CA) in current- or voltage-clamp mode were made usually from pyramidal neurons in layer III of the medial EC visually identified with infrared videomicroscopy (Olympus BX51WI) and differential interference contrast optics. Unless stated otherwise, recording electrodes were filled with (in mM) 130 K⁺-glucconate, 0.5 EGTA, 2 MgCl2, 5 NaCl, 2 ATP2Na, 0.4 GTP-Na, and 10 HEPES, pH 7.4. The extracellular solution comprised (in mM) 130 NaCl, 24 NaHCO3, 3.5 KCl, 1.25 NaH2PO4, 2.5 CaCl2, 1.5 MgCl2, and 10 glucose, saturated with 95% O2 and 5% CO2, pH 7.4. Because NE has been shown to increase GABA release (29) and inhibit glutamatergic transmission (27, 28) in the EC, subiculum, and hippocampus, were cut using a vibrating blade microtome (VT1000S, Leica, Wetzlar, Germany) from 13- to 20-day-old Sprague-Dawley rats as described previously (29, 32–35). After being deeply anesthetized with isoflurane, rats were decapitated and their brains were dissected out in ice-cold saline solution that contained (in mM) 130 NaCl, 24 NaHCO3, 3.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 5.0 MgCl2, and 10 glucose, saturated with 95% O2 and 5% CO2, pH 7.4. Slices were initially incubated in the above solution at 35 °C for 40 min for recovery and then kept at room temperature (−24 °C) until use. All animal procedures conformed to the guidelines approved by the University of North Dakota Animal Care and Use Committee.

Whole Cell Recordings from the EC Neurons—Whole cell patch clamp recordings using an Axopatch 200B or two Multi-clamp 700B amplifiers (Molecular Devices, Sunnyvale, CA) in current- or voltage-clamp mode were made usually from pyramidal neurons in layer III of the medial EC visually identified with infrared videomicroscopy (Olympus BX51WI) and differential interference contrast optics. Unless stated otherwise, recording electrodes were filled with (in mM) 130 K⁺-glucconate, 0.5 EGTA, 2 MgCl2, 5 NaCl, 2 ATP2Na, 0.4 GTP-Na, and 10 HEPES, pH 7.4. The extracellular solution comprised (in mM) 130 NaCl, 24 NaHCO3, 3.5 KCl, 1.25 NaH2PO4, 2.5 CaCl2, 1.5 MgCl2, and 10 glucose, saturated with 95% O2 and 5% CO2, pH 7.4. Because NE has been shown to increase GABA release (29) and inhibit glutamatergic transmission (27, 28) in the EC, the preceding extracellular solution was routinely supplemented with bicuculline (10 μM) and CGP55845 (1 μM) to block GABA_A and GABA_B responses, respectively, and 6,7-dinitroquinoxaline-2,3(1H,4H)-dione (10 μM) and dl-2-amino-5-phosphonovaleric acid (50 μM) to block glutamatergic transmission. Under these conditions, the excitability of pyramidal neurons in layer III was not affected by the indirect effects of NE on GABAergic and glutamatergic transmission. Data were filtered at 2 kHz, digitized at 10 kHz, acquired and analyzed using pCLAMP 9 software (Molecular Devices).

Action potential firing was recorded from pyramidal neurons in layer III of the EC. Because gradual dialysis of K⁺ into cells changed the membrane potential to ~−50 mV to induce action potential firing, NE was applied after the action potential firing had been stable for 5–10 min. To avoid potential desensitization induced by repeated applications of NE, one slice was limited to only one application of NE. Frequency of action potentials was calculated by Mini Analysis 6.0.1 (Synaptosoft Inc., Decatur, GA).

Holding currents at −55 mV were recorded from layer III pyramidal neurons as well as the neurons in layer V/VI in some experiments. The preceding extracellular solution was supplemented with tetrodotoxin (0.5 μM) to block action potential firing. Because gradual dialysis of K⁺ into cells changed the holding currents, we began our recordings after waiting for ~10 min from the formation of whole cell configuration unless stated otherwise. Holding currents at −55 mV were recorded every 3 s and then averaged per minute. We subtracted the average of the holding currents recorded for the last minute prior to the application of NE from those recorded at different time points to zero the basal level of holding currents for better comparison.

The voltage-current relationship was obtained by using a ramp protocol from −140 mV to −70 mV at a speed of 0.1 mV/ms. We compared the voltage-current curves recorded before and during the application of NE for ~3–4 min when the effect of NE was maximal.

Expression of α2A ARs and K₂P Channels in HEK293 Cells and Electrophysiological Recordings from the Transfected Cells—A cDNA construct containing the human α2A AR subtype (GenBank™ accession number NM_000681) subcloned into pcDNA3.1 (Clontech, Palo Alto, CA) was purchased from Missouri University Science and Technology cDNA Resource Center. cDNA constructs coding for TREK-2 (NM_021161, subcloned into the pCMV6-XL4 vector), TREK-1 (NM_014217, subcloned into the pCMV6-entry vector), TWIK-1 (NM_002245, subcloned into pCMV6-XL5 vector), or TREK (NM_181840, subcloned into pCMV6-XL5 vector) were purchased from Origene (Rockville, MD). cDNA constructs coding for TASK-1 (AF_031384) and TASK-3 (AF_391084) were subcloned into pcDNA3.1 (35) were generous gifts from Dr. Douglas A. Bayliss (University of Virginia, Charlottesville, VA). In addition, a previously characterized PKA-insensitive TREK-2 mutant (S595A) subcloned into pcDNA3.1 (36) was a generous gift from Dr. Donghee Kim (Rosalind Franklin University of Medicine and Science, Chicago, IL). An empty pEGFP N-3 green fluorescent protein (GFP) fusion protein vector (GenBank™ accession number U57609) was purchased from Clontech. Dulbecco’s minimum essential medium and fetal bovine serum were purchased from Atlanta Biologicals (Atlanta, GA). Cell culture grade penicillin and streptomycin was purchased from Mediatech, Inc. (Herndon, VA).

Human embryonic kidney (HEK) 293 cells obtained from American Type Culture Collection (Manassas, VA) were maintained in Dulbecco’s minimum essential medium containing 10% fetal bovine serum, penicillin (100 units/ml) and streptomycin (100 units/ml). Confluent HEK293 cells were washed in Hank’s balance salt solution, trypsinized, and seeded at the appropriate density in 35-mm dishes to ensure 40–50% cell confluence within 24 h. Transient transfection of the cDNA...
constructs was performed after 24 h with TransIT-T293 transfection reagent according to the manufacturers protocol (Mirus Bio Corp., Madison, WI) using a 6-μl reagent per 3-μg cDNA ratio for the transfection mixture. Transfected HEK293 cells were subsequently used for electrophysiological recordings 24–48 h post-transfection.

Holding currents at −55 mV were recorded from the HEK293 cells that showed fluorescence under a fluorescence microscope (Olympus IX70) by whole cell recordings. The extracellular solution contained (in mM) 130 NaCl, 3 KCl, 2 MgCl₂, 2 CaCl₂, 1.25 NaH₂PO₄, 10 HEPES, and 10 glucose. pH was adjusted to 7.4 using NaOH and HCl. The above K⁺-gluconate internal solution was used for this experiment. A continuous gravity perfusion system (flow, 5–7 ml/min) was used to change solutions.

**Immunocytochemistry**—Rats (18 days old) were anesthetized with pentobarbital sodium (50 mg/kg) and then perfused transcardially with 0.9% NaCl followed by 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS). Brains were rapidly removed and postfixed in the same fixative for an additional 2 h. After postfixation, brains were cryoprotected with 30% sucrose in PBS for 12 h and then cut into 20-μm slices in thickness horizontally in a Leica cryostat (CM 3050 S) at −21 °C. Slices were washed in 0.1 M PBS and then treated with 0.3% hydrogen peroxide (H₂O₂) to quench endogenous peroxidase activity. After being rinsed in 0.1 M PBS containing 1% Triton X-100 and 1.5% normal donkey serum for 30 min, slices were incubated with the primary antibodies (goat anti-α₂A AR polyclonal antibody, sc-31357, or anti-TREK-2 polyclonal antibody, sc-11559, Santa Cruz Biotechnology, Santa Cruz, CA) at a dilution of 1:100 at 4 °C for 12 h. Slices were incubated at room temperature initially with biotinylated donkey anti-goat IgG (ABC Staining System, Santa Cruz Biotechnology) for 1 h, and then with avidin-biotin complex (ABC Staining System) for 30 min. After each incubation, slices were washed three times for a total of 30 min. Diaminobenzidine (ABC Staining System) was used for a color reaction to detect the positive signals. Finally, the coverslips with the stained cells were subsequently used for electrophoretic transfer system (Bio-Rad). Blots were blocked with 5% powdered milk, and then incubated with either TREK-2 (1:500) or α₂A AR (1:500) primary antibody overnight at 4 °C followed by incubation with the secondary antibody (donkey anti-goat IgG-horseradish peroxidase, 1:2000) for 1 h at room temperature. Tris-buffered saline with 1% Tween 20 was used to wash the blots three times (10 min each) after incubation with both primary and secondary antibodies. Immunoreactive bands were visualized by SuperSignal West Pico Chemiluminescent Substrate (Pierce) and detected by a Biospectrum Imaging System (UVP, Upland, CA).

**Data Analysis**—Data are presented as the means ± S.E. An NE concentration-response curve was fit by using the Hill equation: $I = I_{\text{max}} \times \left[ 1 + \left( \frac{EC_{50}}{[\text{ligand}]} \right)^p \right]$, where $I_{\text{max}}$ is the maximum response, $EC_{50}$ is the concentration of ligand producing a half-maximal response, and $n$ is the Hill coefficient. Student’s paired or unpaired t test or analysis of variance was used for statistical analysis as appropriate; p values are reported throughout the text and significance was set as $p < 0.05$. The N number in the text represents the cells examined.

**Chemicals**—(p)-cAMPS, tertiapin, CGP 55845, pertussis toxin, and guanosine-5'-O-(2-thiodiphosphate) (GDP-β-S) were from BIOMOL (Plymouth Meeting, PA), Corynathine, propranolol, yohimbine, UK14,304, BRL44408, imiloxan, and MDL-12,330A were purchased from Tocris (Ellisville, MO). Antibodies to α₂A ARs (sc-31357), TWIK-1 (sc-11483), TASK-1 (sc-32067), TASK-3 (sc-11322), TRESK (sc-51240), TREK-1 (sc-11554), and TREK-2 (sc-11559) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Other chemicals were products of Sigma-Aldrich.

**RESULTS**

**NE Inhibits the Neuronal Excitability in the Superficial Layers with No Effects on the Deep Layers of the EC**—The EC can be divided into six layers (layers I–VI, Fig. 1A) (38). Layer I is the molecular layer, which has a scarcity of cells, whereas layer IV is the cell-sparse, fiber-rich narrow layer that constitutes the lamina dissecans. Thus the EC is actually classified as the superficial layers (layers II–III) that provide innervations to the hippocampus and the deep layers (layers V–VI) that receive hippocampal outputs. We initially examined the effects of NE on neuronal excitability in the superficial layers. Because the effects of NE in layer II have been studied previously (27, 28), we focused on layer III. Pyramidal neurons are the principal cells in layer III,
Adrenergic Activation of TREK-2 in the EC

We examined the effects of NE on neuronal excitability by recording action potential firing from the pyramidal neurons in layer III in current-clamp mode. The resting membrane potentials of these neurons were $-61.1 \pm 1.3$ mV ($n = 12$) immediately after the formation of whole cell configuration, and thus these neurons did not fire spontaneous action potentials. We therefore injected a positive current to bring the membrane potential to $-50$ mV to induce action potential firing. To prevent potential influences of NE-induced changes in GABAergic and glutamatergic transmission, we included in the extracellular solution 6,7-dinitroquinoxaline-2,3(1H,4H)-dione (10 $\mu$M), and dl-2-amino-5-phosphonovaleric acid (50 $\mu$M) to block glutamatergic, and bicuculline (10 $\mu$M) and CGP55845 (1 $\mu$M) to block GABAergic transmission. Under these conditions, application of NE (100 $\mu$M) significantly reduced the frequency of action potential firing ($28 \pm 5\%$ of control, $p < 0.001$, Fig. 1A, B and C) in 12 out of 12 pyramidal neurons examined suggesting that NE reduces the excitability of pyramidal neurons in layer III of the EC. The EC50 of NE to reduce pyramidal neuron excitability was calculated to be 23 $\mu$M (Fig. 1D).

To test whether the inhibitory effect of NE on action potential firing frequency was mediated by NE-induced hyperpolarization, we recorded NE-induced changes in resting membrane potential in the presence of bicuculline (10 $\mu$M), CGP55845 (1 $\mu$M), 6,7-dinitroquinoxaline-2,3(1H,4H)-dione (10 $\mu$M), dl-2-amino-5-phosphonovaleric acid (50 $\mu$M), and tetrodotoxin (0.5 $\mu$M) to block potential indirect effects from synaptic transmission. A negative current ($-50$ pA for 500 ms) was injected every 5 s to assess the changes of input resistance induced by NE (Fig. 1E). Under these circumstances, application of NE (100 $\mu$M) generated membrane hyperpolarization (control: $-61.6 \pm 0.8$ mV; NE: $-64.5 \pm 0.7$ mV, $n = 6$, $p = 0.002$, Fig. 1E and F) and reduced the input resistance (control: 280.4 $\pm$ 5.2 $\Omega \cdot$ mV; NE: 188.1 $\pm$ 7.9 $\Omega \cdot$ mV; $n = 6$, $p < 0.001$, Fig. 1E) suggesting that NE increases membrane conductance. We then used voltage-clamp mode and recorded the holding currents at $-55$ mV, a potential close to the resting membrane potential of these neurons. Under these conditions, application of NE (100 $\mu$M) generated an outward holding current (maximal effect at the third minute after the beginning of NE application, 20.4 $\pm$ 1.6 pA, $n = 10$, $p < 0.001$, Fig. 1G). Together, these results indicate that NE inhibits the excitability of layer III pyramidal neurons by generating membrane hyperpolarization in the EC.

About 54% of the neurons in layer II of the EC are responsive to NE (27, 28). Our results demonstrated that every pyramidal neuron examined in layer III of the EC was responsive to NE (27, 28). These results together indicate that NE inhibits the excitability
of neurons in the superficial layers of the EC. However, the effects of NE on the deep layer neurons have not been examined. We accordingly studied the effects of NE on neuronal excitability in the deep layers by recording the holding currents at −55 mV from neurons in layer V and layer VI. Larger pyramidal neurons are the principal cells in layer V whereas small, densely packed neurons are the major cell type in layer VI. However, application of NE (100 μM) failed to change the holding currents recorded from layer V (∼4.5 ± 3.6 pA, n = 15, p = 0.23, Fig. 1H) and layer VI (1.1 ± 1.0 pA, n = 10, p = 0.31, Fig. 1H) neurons. These results suggest that NE selectively inhibits neuronal excitability in the superficial layers of the EC with no effects on the deep layers. Because the maximal response ratio was observed in layer III pyramidal neurons, we recorded from this layer for the rest of the experiments to further explore the mechanisms underlying NE-mediated inhibition in the EC.

Ne Depresses Neuronal Excitability via Activation of \( \alpha_2 \) ARs—NE possesses high potency for \( \alpha_1 \), \( \alpha_2 \), and \( \beta \) ARs but has weak activity on \( \beta_2 \) ARs. Activation of these receptors has been shown to generate opposite effects in basolateral amygdala neurons (41). We next examined the roles of these receptors in NE-induced inhibition of neuronal excitability. Application of corynathine (100 μM), a selective \( \alpha_2 \) AR block, failed to alter NE-induced increases in outward holding currents (19.9 ± 2.1 pA, n = 5, p < 0.001, Fig. 2A). Neither did application of propranolol (100 μM), a \( \beta \) AR antagonist, significantly change NE-induced outward holding currents (21.9 ± 4.3 pA, n = 5, p = 0.007, Fig. 2B). However, application of yohimbine (50 μM), an \( \alpha_2 \) AR antagonist, completely prevented NE-induced changes in outward holding currents (0.7 ± 1.8 pA, n = 5, p = 0.73, Fig. 2C). Furthermore, application of UK14,304 (50 μM), a selective \( \alpha_2 \) AR agonist, induced an outward holding current (13.8 ± 1.9 pA, n = 5, p = 0.002, Fig. 2D). Collectively, these results suggest that NE inhibits neuronal excitability via activation of \( \alpha_2 \) ARs in the EC.

\( \alpha_2 \) AR subtypes are classified as \( \alpha_{2A}, \alpha_{2B}, \) and \( \alpha_{2C} \) (31). We next identified the roles of these three subtypes of \( \alpha_2 \) ARs in NE-induced hyperpolarization by combining pharmacological approaches and knock-out (KO) animal models. Pretreatment of slices with and continuous bath application of BRL44408 (3 μM), a selective \( \alpha_{2A} \) AR blocker, significantly reduced NE-induced increases in outward holding currents (5.6 ± 2.8 pA, n = 10, p < 0.001 versus NE alone, Fig. 2D), whereas NE-induced increases in outward holding currents
Adrenergic Activation of TREK-2 in the EC

were not significantly altered when slices were treated in the same fashion with imiloxan (3 μM, 17.9 ± 1.9 pA, n = 6, p = 0.36 versus NE alone, Fig. 2D), a selective α2A AR antagonist, or MK-912 (3 μM, 17.1 ± 2.5 pA, n = 7, p = 0.27 versus NE alone, Fig. 2D), a selective α2C AR antagonist. In accordance with these pharmacological results, application of NE (100 μM) failed to alter the holding currents significantly in 16 slices cut from 3 α2A KO mice (42) (0.6 ± 0.8 pA, n = 16 slices, p = 0.42, Fig. 2E), whereas NE-induced outward holding currents were still observed in α2C KO mice (42) (18.6 ± 2.2 pA, n = 13 slices from 3 mice, p < 0.001, Fig. 2E) and wild-type mice (21.4 ± 2.4 pA, n = 12 slices from 3 wild-type mice, p < 0.001, Fig. 2E). Together, these results indicate that NE inhibits the excitability of pyramidal neurons by activating α2A ARs.

To confirm the electrophysiological data further, we used immunocytochemistry and Western blot to detect the expression of α2A ARs in the EC. Immunoreactivity of α2A ARs was detected in both the superficial and deep layers (Fig. 2F). A band of ~67 kDa was detected from the lyates of the EC by Western blot (Fig. 2G), consistent with the reported molecular mass of α2A ARs (43). The specificity of α2A AR antibody was further confirmed by the result showing that the immunofluorescence of α2A ARs was detected only in HEK293 cells co-expressing α2A ARs and GFP but not in HEK293 cells expressing GFP alone (Fig. 2H).

NE-induced Hyperpolarization Is Dependent on Gα Proteins and Requires PKA Activity—α2A ARs are coupled to Gα proteins resulting in inhibition of cAMP production and PKA activity (31). We next examined the roles of this intracellular pathway in NE-induced inhibition of neuronal excitability in the EC. We replaced the intracellular GTP with GDP-S (4 mM), a G-protein inactivator, and recorded NE-induced changes in holding currents at −55 mV. In the presence of GDP-β-S, NE did not significantly change the holding currents (−9.4 ± 3.6 pA, n = 5, p = 0.06, Fig. 3A) suggesting that NE-induced hyperpolarization is G-protein-dependent. We then identified the roles of Gαi proteins by using pertussis toxin (PTX), an inhibitor of Gαi/o proteins. Slices were pretreated with PTX (500 ng/ml) in the extracellular solution continuously oxygenated with 95% O2 and 5% CO2 for ~8 h. Bath application of NE (100 μM) failed to significantly increase the outward holding currents in slices pretreated with PTX (2.4 ± 1.1 pA, n = 5, p < 0.001, Fig. 3B), whereas treatment of slices for the same period in the same condition without PTX failed to change NE-induced increases in outward holding currents (24.5 ± 3.6 pA, n = 5, p = 0.003, data not shown) suggesting that the PTX-sensitive G-proteins are involved in NE-induced inhibition of neuronal excitability in the EC.

The primary function of α2A ARs is to inhibit adenylyl cyclase (AC) activity and to reduce the levels of cAMP thereby resulting in an inhibition of PKA (31). We next determined the roles of AC and PKA in NE-induced hyperpolarization. Intracellular dialysis of MDL-12,330A (2 mM), an AC inhibitor, via the recording pipettes for ~30 min induced an outward holding current (35.4 ± 8.3 pA, n = 8, p = 0.004, Fig. 3C). Application of NE (100 μM) in the continuous presence of MDL-12,330A failed to further increase the outward holding currents significantly (0.3 ± 0.9 pA, n = 8, p = 0.75, Fig. 3C) suggesting that the activity of AC is required for NE-induced hyperpolarization. Likewise, intracellular application of (R)-cAMPS (1 mM), a specific PKA inhibitor, via the recording pipettes for ~20 min after the formation of whole cell configuration induced an outward holding current (37.8 ± 13.1 pA, n = 6, p = 0.03, Fig. 3D). Subsequent application of NE (100 μM) did not significantly increase the outward holding currents (0.9 ± 1.6 pA, n = 6, p = 0.6, Fig. 3D).
Adrenergic Activation of TREK-2 in the EC

The above results support the notion that AC-cAMP-PKA pathway has a tonic control over the holding currents and NE-induced hyperpolarization is mediated by inhibiting this pathway. If this is the case, elevation of intracellular cAMP level should generate depolarization and alleviate the hyperpolarization effect of NE. We therefore bath-applied forskolin (20 μM, an AC activator) and 3-isobutyl-1-methylxanthine (1 mM, a phosphodiesterase inhibitor) to increase intracellular cAMP concentration. This treatment generated an inward holding current (−23.9 ± 3.8 pA, n = 5, p = 0.003, Fig. 3E) suggesting that increases in intracellular cAMP concentration produce depolarization. In the presence of forskolin and 3-isobutyl-1-methylxanthine, application of NE (100 μM) generated a much smaller increase in outward holding currents (9.3 ± 1.0 pA, n = 5) compared with control (20.4 ± 1.6 pA, n = 10, p < 0.001, Fig. 3E). Similarly, bath application of 8-CPT-cAMP (500 μM), a membrane-permeant cAMP analog, induced an inward holding current (−24.3 ± 4.9 pA, n = 6, p = 0.004, Fig. 3F) and significantly reduced NE-induced increases in outward holding currents (control: 20.4 ± 1.6 pA, n = 10, 8-CPT-cAMP: 8.7 ± 0.3 pA, n = 6, p < 0.001, Fig. 3F). Together, these results indicate that activation of α2A ARs activates Gαq resulting in an inhibition of the AC-cAMP-PKA pathway to decrease neuronal excitability in the EC.

NE-induced Hyperpolarization Is Mediated by Activation of Two-pore Domain K⁺ Channels—We then tested the hypothesis that NE generates membrane hyperpolarization by activating a background K⁺ conductance. First, we replaced the intracellular K⁺ with the same concentration of Cs⁺ on the basis that, if K⁺ channels are involved, replacement of intracellular K⁺ with Cs⁺ should block NE-induced increases in outward holding currents, because K⁺ channels are not permeable to intracellular Cs⁺. Application of NE (100 μM) did not significantly change the holding currents (0.4 ± 0.6 pA, n = 8, p = 0.49, Fig. 4A) when intracellular K⁺ was replaced by Cs⁺. Second, if NE generates hyperpolarization via activation of K⁺ channels, the NE-induced currents should have a reversal potential that is close to the reversal potential of K⁺. We measured the reversal potential of the NE-induced currents using a ramp protocol (from −140 mV to −70 mV) prior to and during the application of NE. Application of NE (100 μM) in the presence of 3.5 mM K⁺ induced a net current that had a reversal potential of −97.7 ± 1.6 mV (n = 6, Fig. 4B), close to the theoretical K⁺ reversal potential calculated by the Nernst equation (−92.2 mV) suggesting that NE produces membrane hyperpolarization by activating a background K⁺ conductance. Third, if NE-induced hyperpolarization was mediated by activation of K⁺ channels, increases in extracellular K⁺ concentration should reduce K⁺ concentration gradient and diminish NE-induced increases in outward holding currents. Elevation of extracellular K⁺ concentration to 10 mM significantly reduced NE-induced enhancement of outward holding currents (3.5 mM K⁺: 20.4 ± 1.6 pA, n = 10, 10 mM K⁺: 1.1 ± 1.3 pA, n = 6, p < 0.001, Fig. 4C). Together, these results indicate that NE generates membrane hyperpolarization by activating a background K⁺ conductance.

We then determined the properties of the K⁺ channels involved in NE-induced hyperpolarization by applying the classical K⁺ channel blockers. NE-induced increases in outward holding currents were not significantly altered by including, in the extracellular solution, tetraethylammonium (TEA, 10 mM, 17.5 ± 3.3 pA, n = 5, p = 0.4, Fig. 4C), Cs⁺ (3 mM, 15.9 ± 2.3 pA, n = 6, p = 0.12, Fig. 4C), and 4-aminoopyridine (2 mM, 15.5 ± 1.5 pA, n = 5, p = 0.1, Fig. 4C) suggesting that NE-activated K⁺ channels are insensitive to the classic K⁺ channel blockers. Whereas inward rectifier K⁺ channels are involved in controlling resting membrane potential, they are unlikely to be the channels activated by NE, because these channels are also sensitive to TEA and Cs⁺. Moreover, application of the inward rectifier K⁺ channel blocker, tertiapin (50 mM), failed to block the effect of NE (16.1 ± 2.6 pA, n = 5, p = 0.2, versus NE alone, Fig. 4C).

The two-pore domain K⁺ channels (K₂p) are involved in controlling resting membrane potentials, and they are insensitive to the classic K⁺ channel blockers (TEA, 4-aminoopyridine, and Cs⁺). We next examined the roles of K₂p in NE-induced membrane hyperpolarization. K₂p channels are grouped according to sequence and functional similarities into six subfamilies: TWIK, THIK, TREK, TASK, TALK, and TRESK (44, 45), some of which are sensitive to Ba²⁺. We therefore tested the roles of Ba²⁺ in NE-induced membrane hyperpolarization. Inclusion of Ba²⁺ (3 mM) in the extracellular solution 

![FIGURE 4. NE-mediated hyperpolarization is mediated by activation of a background K⁺ channel. A, replacing K⁺ in the intracellular solution with the same concentration of Cs⁺ blocked NE-induced increases in outward holding currents (n = 8). B, voltage-current relationship induced by a ramp protocol from −140 mV to −70 mV at a speed of 0.1 mV/ms prior to and during the application of NE (100 μM). Subtraction of the current prior to from the current during the application of NE generated a net current. The traces were averages from six cells. Note that the reversal potential was −97.7 ± 1.6 mV (n = 6), close to the calculated K⁺ reversal potential (−92.2 mV). C, NE-induced increases in outward holding currents were insensitive to extracellular application of the classic K⁺ channel blockers (TEA, 10 mM, n = 5, p = 0.4; Cs⁺, 3 mM, n = 6, p = 0.12; 4-aminoopyridine [4-AP], 2 mM, n = 5, p = 0.1; tertiapin, 50 mM, n = 5, p = 0.2, versus application of NE alone) but significantly reduced when the extracellular K⁺ concentration was increased to 10 mM (n = 6, p < 0.001). D, inclusion of Ba²⁺ (3 mM) in the extracellular solution induced an inward holding current per se but prevented NE-induced increases in outward holding currents (n = 6).](https://example.com/figure4)
lular solution per se generated an inward holding current \((-47.8 \pm 13.0 \, \text{pA}, n = 6, p = 0.02, \text{Fig. 4D})\) suggesting that \(\text{Ba}^{2+}\)-sensitive \(K_{2P}\) channels contribute substantially to controlling resting membrane potentials in layer III pyramidal neurons. In the presence of \(\text{Ba}^{2+}\), application of NE (100 \, \text{mM}) failed to change the holding currents significantly \((-1.6 \pm 3.1 \, \text{pA}, n = 6, p = 0.6, \text{Fig. 4D})\). This result suggests that NE-induced membrane hyperpolarization is mediated by a \(\text{Ba}^{2+}\)-sensitive \(K_{2P}\) channel.

**TREK-2 Channels Are Required for NE-induced Hyperpolarization**—We took the advantage that the sensitivities of \(K_{2P}\) channels to \(\text{Ba}^{2+}\) have been well documented to further identify the involved type(s) of \(K_{2P}\) channels. Among the \(K_{2P}\) channels, TASK-1 (46), TASK-3 (46, 47), TREK-1 (48), TREK-2 (46), TWIK-1 (49), and TRESK (50) are sensitive to \(\text{Ba}^{2+}\). Because our results showed that NE-mediated hyperpolarization was sensitive to \(\text{Ba}^{2+}\), it was reasonable to speculate that the effects of NE were mediated via activation of one or more of these \(K_{2P}\) channels. Because specific blockers for these \(K_{2P}\) channels are not available, we tried to identify the roles of these \(K_{2P}\) channels in NE-induced hyperpolarization by applying, via the recording pipettes, their specific antibodies. The rationale for this experiment was that the epitopes for all these antibodies are located to the intracellular C or N terminus of the \(K_{2P}\) channels (51), and the specific bindings of the large IgG molecules to the channels would interfere with the functions of the channels and block or at least reduce the effects of NE. To ensure complete intracellular dialysis of these antibodies because they are large IgG molecules, we waited for \(-65\) min after the formation of whole cell recordings. We initially tested whether long-time infusion of antibody had any nonspecific effects on NE-induced increases in outward holding currents. Application of control IgG (40 \, \text{μg/ml}) via the recording pipettes did not significantly change NE-induced outward holding currents (Control: 20.4 \pm 1.6 \, \text{pA}, n = 10, \text{IgG:} 21.6 \pm 2.1 \, \text{pA}, n = 5, p = 0.67, \text{Student's unpaired t test}) suggesting that intracellular infusion of IgG had no nonspecific effects on NE-induced increases in outward holding currents. Intracellular application of antibodies to TASK-1 (n = 5, p = 0.37, \text{Fig. 5A}), TASK-3 (n = 5, p = 0.25, \text{Fig. 5B}), TWIK-1 (n = 5, p = 0.99, \text{Fig. 5C}), TRESK (n = 5, p = 0.6, \text{Fig. 5D}), and TREK-1 (n = 5, p = 0.32, \text{Fig. 5E}) failed to change NE-induced increases in outward holding currents significantly compared with the effect of NE when control IgG was applied via the recording pipettes. However, application of antibody to TREK-2 significantly reduced NE-induced increases in outward holding currents (2.9 \pm 0.9 \, \text{pA}, n = 6, p < 0.001 \text{ versus control IgG, \text{Fig. 5F}}). These results indicate that NE inhibits neuronal excitability selectively by activating TREK-2 channels in the EC. We further corroborated the expression of TREK-2 channels in the EC by immunocytochemistry and Western blot. Immunoreactivity of TREK-2 channels was detected in each layer of the EC (\text{Fig. 6A}). The expression of TREK-2 channel proteins in the EC was confirmed by Western blot. A band that had a molecular mass of \(-59\) kDa was detected in the lysates of the EC, whereas pretreatment of the TREK-2 antibody with the corresponding blocking peptide prevented the detection of the band (\text{Fig. 6B}). The measured molecular weight for TREK-2 was close to the reported molecular weight of TREK-2 (52, 53). To test the specificity of the TREK-2 antibody further, we transfected HEK293 cells with GFP alone or GFP plus TREK-2 channels. Immunoreactivity of TREK-2 channels was detected only in HEK293 cells transfected with both GFP and TREK-2 channels but not in HEK293 cells transfected with GFP alone (\text{Fig. 6C}).

One may argue that the above negative results obtained by applying the antibodies to TASK-1, TASK-3, TREK-1, TWIK-1, and TRESK via the recording pipettes were due to the inability of these antibodies to recognize the native conformation of these channels. We addressed this issue by applying, via the recording pipettes, the antibod-
Adrenergic Activation of TREK-2 in the EC

To further confirm the roles of TREK-2 channels in NE-mediated hyperpolarization, we co-transfected α2A ARs with TREK-2 channels in HEK293 cells and recorded the holding currents at −55 mV from the transfected cells. Application of NE (100 μM) generated an outward holding current in the cells co-transfected with α2A ARs and TREK-2 channels (229.3 ± 39.9 pA, n = 9, p < 0.001, Fig. 7, A and B), whereas application of the same concentration of NE failed to significantly change the holding currents in HEK293 cells transfected with TREK-2 channels alone (9.3 ± 12.4 pA, n = 5, p = 0.49, Fig. 7, A and B).

To test whether the effects of NE on the holding currents in the transfected cells were mediated by K⁺ channels, we applied a ramp protocol (from −140 mV to −60 mV at a rate of 0.1 mV/ms) before and during the application of NE. The reversal potential for the NE-induced currents was −93.8 ± 1.4 mV (n = 9) in cells co-transfected with α2A ARs and TREK-2 (Fig. 7C). The measured reversal potential was close to the calculated K⁺ reversal potential (−96.1 mV) in our recording conditions suggesting that the effects of NE were mediated by inhibition of TREK-2 channels in the transfected cells.

**NE-mediated Hyperpolarization Is Dependent on PKA-mediated Phosphorylation on Serine 359 of TREK-2 Channels**—Up to now, our results support an action mode in which activation of α2A ARs by NE activates Gα, proteins resulting in decreased activity of AC-cAMP-PKA pathway and increased function of TREK-2 channels to generate hyperpolarization in the EC. Consistent with our results, both TREK-1 (48, 54) and TREK-2 (55, 56) channels are inhibited by PKA-mediated phosphorylation. TREK-2 channels are phosphorylated by PKA on serine 359 of the C terminus (56). Accordingly, we tested the role of this phosphorylation site in NE-mediated hyperpolarization. We co-expressed in HEK293 cells α2A ARs with a mutant TREK-2 channel in which serine 359 was mutated to alanine (S359A) (36) to nullify PKA-mediated phosphorylation of TREK-2 channels. Alanine substitution of this site did not prevent the expression and functions of TREK-2 channels in HEK293 cells (36). However, application of NE (100 μM) failed to change the holding currents significantly in HEK293 cells co-expressing α2A ARs and TREK-2 S359A mutant.

**DISCUSSION**

In the present study, we have addressed four questions that are essential for understanding NE-induced inhibition of neuronal excitability in the EC. First, we systematically examined the effects of NE on neuronal excitability in each layer of the EC, and our results reveal that NE only inhibits neuronal excitability in the superficial layers with the highest response ratio in layer III pyramidal neurons. NE does not alter the excitabilities of neurons located in the deep layers (layer V/VI) suggesting that NE inhibits the inflow of excitatory information from the deep layers to the superficial layers of EC.
Adrenergic Activation of TREK-2 in the EC

EC to the hippocampus. Second, using both pharmacological methods and knockout animal models we have identified that α2A ARs are required for NE-mediated hyperpolarization in the EC. Third, we have found that TREK-2 channels are the types of K⁺ channels that are involved in NE-induced hyperpolarization in the EC. Finally, we have determined that NE-mediated inhibition of entorhinal neurons requires the functions of Goᵢ proteins and AC-cAMP-PKA pathway. As schematically illustrated in Fig. 8, our results support an action mode in which activation of α₂A ARs by NE down-regulates AC-cAMP-PKA pathway and disinhibits the tonic inhibition of TREK-2 channels by this pathway resulting in a depression of EC neuronal excitability.

Ionic Mechanisms underlying NE-mediated Inhibition of Neuronal Excitability in the EC—Background K⁺ channels are the major determinants of neuronal membrane potential, and their functional modification is one of the principal mechanisms by which neurotransmitters modulate neuronal excitability. Kᵢ₂P channels are the major K⁺ channels that are responsible for controlling resting membrane potentials. Kᵢ₂P channels can be grouped according to sequence and functional similarities into six subfamilies: TWIK, THIK, TREP, TASK, TALK, and TREK (44). Our results for the first time reveal that NE inhibits the excitability of entorhinal neurons, particularly the layer III pyramidal neurons, by activating TREK-2, a type of Kᵢ₂P and TRESK (44). Our results for the first time reveal that NE can be grouped according to sequence and functional similarities of channels based on the following bodies of evidence. First, intracellular application of GDP-β-S blocked NE-induced hyperpolarization suggesting that the function of G-proteins is required for the effects of NE. Second, the type of G-protein is identified to be Goᵢ because pretreatment of slices with PTX blocked NE-induced hyperpolarization. Third, application of MDL-12,330A, an AC inhibitor, blocked NE-induced increases in outward holding currents. Fourth, intracellular application of (R)−cAMPS, a specific PKA inhibitor, blocked NE-induced increases in outward holding currents. Finally, application of NE failed to induce membrane hyperpolarization in HEK293 cells co-expressing α₂A ARs with the mutated TREK-2 channels in which the PKA phosphorylation site, serine 359, was mutated to alanine. Together, our results support a scenario in which α₂A AR-mediated activation of Goᵢ leads to a down-regulation of PKA activity resulting in a reduction in the tonic inhibition of TREK-2 channels mediated by PKA. The ultimate result is an up-regulation of TREK-2 channels and hyperpolarization of entorhinal neurons (Fig. 8).

Physiological and Pathological Significances—Neurons in the superficial and deep layers of the EC have distinct functions. Whereas neurons in the superficial layers convey information to the hippocampus, those in the deep layers are the recipients of hippocampal output, and they project the information back to the superficial layers or to other cortices. Our results show that NE inhibits neuronal excitability in the superficial layers with no effects on the deep layers suggesting that NE inhibits the inflow of excitatory inputs from the EC to the hippocampus. Although the reasons that NE failed to modulate the excitability of neurons in the deep layers are unknown, it seems unlikely that lack of α₂A ARs and TREK-2 channels in the deep layer neurons is responsible for the negative results of NE, because these neurons express α₂A ARs (Fig. 2F) and TREK-2 channels (Fig. 6A). Because NE-mediated depression of neuronal excitability requires collaborative efforts of other signals, including G-proteins, AC, cAMP, and PKA, it is conceivable to speculate that one or more of these molecules may be missing in the deep layers of the EC. Because there are numerous isoforms for these intracellular signals, one explanation for the negative results of NE in the deep layers is that the specific isoform of these molecules essential for NE-induced hyperpolarization is not
Adrenergic Activation of TREK-2 in the EC

expressed by the deep layer neurons. Further experiments will be performed to address this issue in the future. Whereas NE generates membrane hyperpolarization in ~54% of the neurons in layer II (28), our results demonstrate that NE-mediated hyperpolarization is observable in each of the pyramidal neurons examined in layer III suggesting that the major effect of NE is on layer III pyramidal neurons. Because the axons of the neurons in layers II and III form two parallel pathways to the hippocampus and exert distinct functions in spatial learning (61), the uneven effects of NE on these two layer neurons may underlie separate roles of NE in different patterns of memories. Furthermore, layer III pyramidal neurons are selectively lost during epilepsy (39, 40), the high response ratio to NE observed in this layer enlightens an important role of NE in epilepsy as well. The excitability of the neurons in the superficial layers of the EC is on layer III pyramidal neurons. Because the axons of the neurons examined in layer III suggesting that the major effect of NE remains unexplored. Our results could explain the detrimental effects of NE on layer III pyramidal neurons. Because the axons of the neurons examined in layer III suggesting that the major effect of NE remains unexplored. Our results could explain the detrimental effects of NE on layer III pyramidal neurons.

Acknowledgments—We greatly appreciate the generous gift of cDNA for the mutant TREK-2 channels (S359A) from Dr. Donghee Kim (Rosalind Franklin University of Medicine and Science, Chicago, IL) and cDNA for TASK-1 and TASK-3 from Dr. Douglas A. Bayliss (University of Virginia, Charlottesville, VA).

REFERENCES

1. Majak, K., and Pitkanen, A. (2003) Eur. J. Neurosci. 18, 1652–1659
2. Dolcos, F., LaBar, K. S., and Cabeza, R. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 2626–2631
3. Steffenach, H. A., Witter, M., Moser, M. B., and Moser, E. I. (2005) Neuron 45, 301–313
4. Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., and Barnes, C. L. (1984) Science 225, 1168–1170
5. Kotzbauer, P. T., Trojanowsk, J. Q., and Lee, V. M. (2001) J. Mol. Neurosci. 17, 225–232
6. Joyal, C. C., Laakso, M. P., Tiisalon, J., Syvalahti, E., Valkman, H., Laakso, A., Alakare, B., Rakkolainen, V., Salokangas, R. K., and Hietala, J. (2002) Biol. Psychiatry 51, 1005–1007
7. Prasad, K. M., Patel, A. R., Muddasani, S., Sweeney, J., and Keshavan, M. S. (2004) Ann. J. Psychiatry 161, 1612–1619
8. Spencer, S. S., and Spencer, D. D. (1994) Epilepsia 35, 721–727
9. Avoli, M., D’Antuono, M., Louvel, J., Kohling, R., Biagioni, G., Pumain, R., D’Arcangelo, G., and Tancredi, V. (2002) Prog. Neurobiol. 68, 167–207
10. Witter, M. P., Groenewegen, H. J., Lopes da Silva, F. H., and Lohman, A. H. (1989) Prog. Neurobiol. 33, 161–253
11. Burwell, R. D. (2000) Ann. N. Y. Acad. Sci. 911, 25–42
12. Steward, O., and Scoville, S. A. (1976) J. Comp. Neurol. 169, 347–370
13. Witter, M. P., Naber, P. A., van Haeften, T., Machielsen, W. C., Rombouts, S. A., Barkhof, F., Scheltens, P., and Lopes da Silva, F. H. (2000) Hippocampus 10, 398–410
14. Witter, M. P., Wouterlood, F. G., Naber, P. A., and Van Haeften, T. (2000) Annu. N. Y. Acad. Sci. 911, 1–24
15. Kohler, C. (1986) J. Comp. Neurol. 246, 149–169
16. Dolforo, C. L., and Amaral, D. G. (1998) J. Comp. Neurol. 398, 49–82
17. Dolforo, C. L., and Amaral, D. G. (1998) J. Comp. Neurol. 398, 25–48
18. van Haeften, T., Baks-te-Bulte, L., Goede, P. H., Wouterlood, F. G., and Witter, M. P. (2003) Hippocampus 13, 943–952
19. Fallon, J. H., Koziell, D. A., and Moore, R. Y. (1978) J. Comp. Neurol. 180, 509–532
20. Palkovits, M., Zaborszky, L., Brownstein, M. J., Fekete, M. I., Herman, J. P., and Kanyicska, B. (1979) Brain Res. Bull. 4, 593–601
21. Wilcox, B. J., and Unnerstall, J. R. (1990) Synapse 6, 284–291
22. Stanton, P. K., Jones, R. S., Mody, I., and Heinemann, U. (1987) Epilepsy Res. 1, 53–62
23. Unnerstall, J. R., Kopajtic, T. A., and Kuhar, M. J. (1984) Brain Res. 319, 69–101
24. Unnerstall, J. R., Fernandez, I., and Orenszan, L. M. (1985) Pharmacol. Biochem. Behav. 22, 859–874
25. Boyajian, C. L., Loughlin, S. E., and Leslie, F. M. (1987) J. Pharmacol. Exp. Ther. 241, 1079–1091
26. Booze, R. M., Crisostomo, E. A., and Davis, J. N. (1993) Synapse 13, 206–214
27. Pralong, E., and Magistretti, P. J. (1995) Eur. J. Neurosci. 7, 2370–2378
28. Pralong, E., and Magistretti, P. J. (1994) Neurosci. Lett. 179, 145–148
29. Lei, S., Deng, P. Y., Porter, J. E., and Shin, H. S. (2007) J. Neurophysiol. 98, 2868–2877
30. Stoop, R., Epinye, S., Meier, E., and Pralong, E. (2000) Neurosci. Lett. 287, 5–8
31. Hein, L. (2006) Cell Tissue Res. 326, 541–551
32. Deng, P. Y., Porter, J. E., Shin, H. S., and Lei, S. (2006) J. Physiol. 577, 497–511
33. Deng, P. Y., and Lei, S. (2006) J. Physiol. 572, 425–442
34. Deng, P. Y., and Lei, S. (2007) J. Neurophysiol. 97, 727–737
35. Deng, P. Y., Poudel, S. K., Rovanathananmee, L., Porter, J. E., and Lei, S. (2007) Mol. Pharmacol. 72, 208–218
36. Kang, D., Choe, C., Cavanaugh, E., and Kim, D. (2007) J. Physiol. 583, 57–69
37. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254
38. Mulders, W. H., West, M. J., and Slomianka, L. (1997) J. Comp. Neurol. 385, 83–94
39. Du, F., and Schwarcz, R. (1992) Neurosci. Lett. 147, 185–188
40. Du, F., Whetsell, W. O., Jr., Abou-Khalil, B., Blumenkopf, B., Lothman, E. W., and Schwarcz, R. (1993) Epilepsy Res. 16, 223–233
41. Buffalari, D. M., and Grace, A. A. (2007) J. Neurosci. 27, 12358–12366
42. Szot, P., Lester, M., Laughlin, M. L., Palminteri, R. D., Liles, L. C., and Weinshenker, D. (2004) Neuroscience 126, 795–803
43. Small, K. M., Schwab, M. R., Glinka, C., Theiss, C. T., Brown, K. M., Semon, C. A., and Liggett, S. B. (2006) Biochemistry 45, 4760–4767
44. Bayliss, D. A., Sirois, J. E., and Talley, E. M. (2003) Mol. Interv. 3, 205–219
45. Lesage, F. (2003) Neuropharmacology 44, 1–7
46. Han, J., Truell, J., Gnatenco, C., and Kim, D. (2002) J. Physiol. 542, 431–444
47. Kim, Y., Bang, H., and Kim, D. (2000) J. Biol. Chem. 275, 9340–9347
48. Fink, M., Duprat, F., Lesage, F., Reyes, R., Romey, G., Heurteaux, C., and Lazdunski, M. (1996) EMBO J. 15, 6854–6862
49. Lesage, F., Guillemaire, E., Fink, M., Duprat, F., Lazdunski, M., Romey, G., and Barhanin, J. (1996) EMBO J. 15, 1004–1011
50. Sano, Y., Inamura, K., Miyake, A., Mochizuki, S., Kitada, C., Yokoi, H., Nozawa, K., Okada, H., Matsushima, H., and Furuichi, K. (2003) J. Biol. Chem. 278, 27406–27412
51. Goldstein, S. A., Bockenhauer, D., O’Kelly, I., and Zilberberg, N. (2001) Nat. Rev. Neurosci. 2, 175–184
52. Kang, D., Kim, S. H., Hwang, E. M., Kwon, O. S., Yang, H. Y., Kim, E. S., Choi, T. H., Park, J. Y., Hong, S. G., and Han, J. (2007) Exp. Dermatol. 16, 1016–1022
53. Simkin, D., Cavanaugh, E. J., and Kim, D. (2008) J. Physiol. 586, 5651–5663
54. Murbartian, J., Lei, Q., Sando, J. J., and Bayliss, D. A. (2005) J. Biol. Chem. 280, 30175–30184
55. Lesage, F., Terrenoire, C., Romey, G., and Lazdunski, M. (2000) J. Biol. Chem. 275, 28398–28405
56. Bang, H., Kim, Y., and Kim, D. (2000) J. Biol. Chem. 275, 17412–17419
57. Chen, X., Talley, E. M., Patel, N., Gomis, A., McIntire, W. E., Dong, B., Viana, F., Garrison, J. C., and Bayliss, D. A. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 3422–3427
58. Veale, E. L., Kennard, L. E., Sutton, G. L., MacKenzie, G., Sandu, C., and Mathie, A. (2007) Mol. Pharmacol. 71, 1666–1675
59. Mathie, A. (2007) J. Physiol. 578, 377–385
60. Chemin, J., Girard, C., Duprat, F., Lesage, F., Romey, G., and Lazdunski, M. (2003) EMBO J. 22, 5403–5411
61. Nakashiba, T., Young, J. Z., McHugh, T. J., Buhl, D. L., and Tonegawa, S. (2008) Science 319, 1260–1264
62. Galeotti, N., Bartolini, A., and Ghelardini, C. (2004) Behav. Brain Res. 153, 409–417
63. Galeotti, N., Bartolini, A., and Ghelardini, C. (2004) Neuroscience 126, 451–460
64. Haapalinna, A., Sirvio, J., and Lammintausta, R. (1998) Eur. J. Pharmacol. 347, 29–40

Adrenergic Activation of TREK-2 in the EC